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ABSTRACT
Purpose: Early detection of gastric cancer is important to improve prognosis. Early detection 
enables local treatment, such as endoscopic submucosal dissection (ESD). Therefore, we 
investigated whether early detection of gastric cancer could reduce healthcare costs by 
comparison according to stage and treatment modalities.
Materials and Methods: Medical care costs were investigated according to tumor stage and 
initial treatment modality in 1,188 patients newly diagnosed with gastric cancer at 7 medical 
institutions from December 2011 to June 2012. Total medical care costs during the first-year 
after diagnosis (total first-year costs) were examined, including the costs of initial treatment, 
post-initial treatment, and inpatient and outpatient visits.
Results: Stage I (75.3%) was the most common cancer stage. ESD was the second most 
common treatment following surgery. Total first-year costs increased significantly from 
stages I to IV. The costs of initial treatment and post-initial treatment were lowest in 
patients with stage I cancer. Among patients with stage I cancer, total first-year costs were 
significantly lower when treated by ESD; in particular, initial ESD treatment costs were much 
lower than others.
Conclusions: The cost of healthcare has increased significantly with increasing cancer stages. 
ESD can greatly reduce medical care costs of gastric cancer. Thus, early detection of gastric 
cancer is important to reduce healthcare costs.
Keywords: Stomach neoplasms; Endoscopic submucosal dissection; Healthcare costs; 
Cancer staging; Early detection of cancer
INTRODUCTION
Early detection of gastric cancer is very important to improve prognosis. Furthermore, early 
detection enables local treatments to preserve the stomach, such as endoscopic submucosal 
dissection (ESD). ESD can be curative for selected cases of early gastric cancer (EGC) [1].
The economic burden of cancer care is important for patients with cancer. Cancer accounts for 
4%–10% of total healthcare costs worldwide, and the rate of inflation of these costs is widely 
viewed as unsustainable from a societal perspective [2]. Cancer care costs can be divided into 
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direct and indirect costs [3]. Direct costs include medical care costs, such as treatment costs, 
and indirect costs are opportunity costs lost due to contracting a disease and death [3,4]. Direct 
costs differ by cancer characteristics, including stage and treatment options [2].
Cancer care cost analyses are usually performed in 3 phases to reflect clinical and cost-
related dynamics, including an initial phase (time following diagnosis, usually up to 1 year), 
a continuing phase (time between initial and final phases), and a final phase (usually 1 year 
before death) [5,6]. Previous studies have reported that a large proportion of cancer care 
costs are incurred during the initial phase [7,8].
Early detection of gastric cancer, and especially treatment modality, can affect healthcare 
costs. However, the effect of ESD on healthcare costs has not been evaluated for gastric 
cancer. Therefore, we investigated whether early detection of gastric cancer could reduce 
healthcare costs by comparison according to stage and treatment modalities.
MATERIALS AND METHODS
Study subjects
The medical records of 1,188 patients newly diagnosed with gastric cancer at 7 medical 
institutions (Seoul St. Mary's Hospital, Asan Medical Center, Yeouido St. Mary's Hospital, 
Gangnam Severance Hospital, St. Vincent Hospital, Uijeongbu St. Mary's Hospital, and 
Severance Hospital) from December 2011 to June 2012 were analyzed retrospectively, 
including initial diagnostic route, initial treatment modality, and tumor stage. The initial 
diagnostic routes included “screening” and “due to symptoms.” Screening was either 
individualized or through national organized gastric cancer screening. Tumor stage was 
based on pathological and clinical findings. Pathological stage was defined using the 7th 
tumor, node, metastasis (TNM) staging system.
Generally, treatments according to the stage are as follows: ESD or surgery for stage I; surgery 
or surgery with adjuvant chemotherapy for stages II and III, and palliative chemotherapy or 
conservative care for stage IV. After treatment, surveillance is conducted every 3–6 months for 
the first-year by medical examination, blood test, endoscopy, and computed tomography.
If several treatments were employed, the initial treatment modality was considered the first 
option as curative treatment. For example, if additional surgery was performed because of 
non-curative resection after ESD, the surgery was considered the initial treatment modality 
for the patient. Thus, initial treatment modalities were categorized into ESD, surgery, surgery 
with adjuvant chemotherapy, palliative chemotherapy, and conservative care.
Exclusion criteria included neoadjuvant chemo- or radiotherapy; follow-up duration <1 year 
after diagnosis, except death; combined with other malignancies within the past 5 years; or 
severe co-morbidities.
Cost definition and estimate
Cancer care costs are divided into direct and indirect costs [3]. Direct costs are medical and 
non-medical care costs. Medical care costs are costs for medical procedures and services 
associated with treatment and cancer care, including costs for hospitalization, outpatient 
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visits, and prescription drugs [9]. Medical care costs for medical procedures associated with 
treatment included all of the costs related to tests, medical procedures, and services after 
diagnosis of gastric cancer. For example, if additional surgery was performed because of 
non-curative resection after ESD, the cost of ESD was considered as medical care costs for 
medical procedures associated with treatment. Thus, the cost of initial treatment is the same 
between surgery only and ESD with additional surgery. However, total medical care costs 
were different; the cost of patients who underwent ESD with additional surgery was higher 
than that of those undergoing surgery only.
Non-medical costs include costs of transportation to healthcare providers, costs associated 
with care, and costs for complementary and alternative medicine [9]. Indirect costs are the 
opportunity costs lost by contracting a disease and death [4].
Medical care costs during the first-year after diagnosis (total first-year costs) were compared 
according to tumor stage and initial treatment modality. Total first-year costs included 
payments for insurance-covered services (insurer payments) and payments for co-insurance 
and uncovered services (patient payments). Cost of initial treatment, the cost after initial 
treatment, and the number of inpatient and outpatient visits were determined. Cost of initial 
treatment only included the cost related to the treatment, and not the cost spent on the 
staging of the cancer.
The cost for initial palliative chemotherapy treatment was defined as the cost for the first 
palliative chemotherapy session; later sessions were included in costs after initial treatment. 
The cost for initial conservative care treatment was defined as the cost for conservative cancer 
treatment during the first admission.
All estimated costs are represented using the 2012 annual exchange rate of 1,100 Korean won 
to 1 USD.
Statistical analyses
The χ2 test was used to examine associations among categorical variables, and 1-way 
analysis of variance was used for non-categorical variables. A P-value <0.05 was considered 
significant. All analyses were performed using SPSS version 18.0 for Windows (SPSS Inc., 
Chicago, IL, USA).
RESULTS
Baseline clinical characteristics of the subjects
Table 1 shows the subjects' clinicopathological features. Most initial diagnoses involved upper 
endoscopy. Stage I was the most common cancer stage (75.3% of all the patients). ESD was 
the second most common initial treatment following surgery. Laparoscopic gastrectomy was 
more common than open or robot-assisted gastrectomy among surgical procedures.
Table 2 shows clinical features according to tumor stage. Organized screening was the most 
common initial diagnostic route for stage I cancer, whereas “due to symptoms” was the most 
common for stage IV. About 42% of stage I cases underwent ESD as an initial gastric cancer 
treatment.
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Medical care costs according to cancer stage
Total first-year costs increased significantly from stage I through stage IV (Fig. 1). The costs of 
initial treatment and post-initial treatment were the lowest for stage I (Fig. 1). Detailed costs 
according to tumor stage are shown in Table 3. Most first-year costs increased from stage I 
through stage IV, except patient and initial treatment costs, which were highest in stage III.
Medical care costs according to initial treatment of stage I cancer
Initial treatment modalities for stage I cancer included ESD, surgery, and surgery with adjuvant 
chemotherapy. Total first-year costs for stage I cancer were significantly lower for ESD and much 
lower for initial ESD treatment than for other modalities (Fig. 2). Costs were detailed according 
to initial treatment modality for stage I cancer in Table 4. Most costs were significantly lower in 
stage I, except the number of admissions, which did not differ among initial stage I treatments.
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Table 1. Baseline clinical characteristics of the subjects
Characteristics Values
Male 798 (67.2)
Age (yr) 61.6±12.0
Initial diagnostic method
Upper endoscopy 1,183 (99.6)
Barium series 2 (0.2)
Others 3 (0.3)
Initial diagnostic route
Organized screening 191 (16.1)
Individualized screening 460 (38.7)
Due to symptoms 332 (27.9)
Unknown 205 (17.3)
Stage
I/II/III/IV 894/103/105/86 (75.3/8.7/8.8/7.2)
Initial treatment
ESD 380 (32.0)
Surgery 527 (44.4)
Laparoscopic 334 (28.1)
Open 166 (14.0)
Robot 27 (2.3)
Surgery with chemotherapy 188 (15.8)
Chemotherapy 76 (6.4)
Conservative care 17 (1.4)
Data shown are number (%) or mean±standard deviation.
ESD = endoscopic submucosal dissection.
Table 2. Clinical characteristics of the subjects according to the tumor stage
Stages I (n=894) II (n=103) III (n=105) IV (n=86) P-value
Male 68.9 62.1 59.0 65.1 0.127
Age (yr) 61.7±11.4 62.7±13.8 62.2±13.5 58.5±14.0 0.158
Initial diagnostic route <0.001
Organized screening 19.0 8.7 11.4 0.0
Individualized screening 38.6 43.7 39.0 33.7
Due to symptoms 22.3 33.0 41.9 64.0
Initial treatment <0.001
ESD 42.5 0.0 0.0 0.0
Surgery 50.2 47.6 24.8 3.5
Surgery with CTx 7.2 48.5 66.7 4.7
CTx 0.0 1.0 6.7 79.1
Conservative care 0.1 2.9 1.9 12.8
Data shown are percentage (%) or mean±standard deviation.
ESD = endoscopic submucosal dissection; CTx = chemotherapy.
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Stage I Stage II Stage III Stage IV
9,000 $
0 $
27,000 $
18,000 $
Total first year cost:
Stage I < II < III < IV
Cost of initial treatment:
Stage I < II, IV, III
Cost after initial treatment:
Stage I < II, III < IV
Fig. 1. Medical care costs according to cancer stage. Total first-year costs increased significantly from stage I 
through stage IV. Initial treatment and post-initial treatment costs were the lowest for stage I (“<” indicates a 
significant difference).
Table 3. Medical care costs according to the stage
Variables Stage I Stage II Stage III Stage IV P-value
Total first-year costs ($) 8,907±5,790 12,956±10,988 18,277±11,489 25,753±15,520 <0.001
Insurer payments 4,412±3,453 7,768±8,886 11,476±7,881 19,559±10,885 <0.001
Patient payments 2,482±2,529 3,463±3,576 5,549±6,183 4,158±4,537 <0.001
Cost of initial treatment 4,700±3,489 6,157±4,161 7,974±5,631 6,478±6,439 <0.001
Cost after initial treatment 2,807±3,317 5,682±6,736 8,510±9,091 17,012±15,577 <0.001
No. of outpatient visits 10.0±7.2 14.0±9.0 17.0±12.0 20.5±17.6 <0.001
No. of admissions 1.3±1.1 2.9±2.8 5.5±5.3 8.7±7.5 <0.001
Data shown are mean±standard deviation.
ESD OP OP with CTx
4,500 $
0 $
13,500 $
9,000 $
Total first year cost:
ESD < OP with CTx < OP
Cost of initial treatment:
ESD < OP with CTx, OP
Cost after initial treatment:
ESD, OP with CTx < OP
Fig. 2. Medical care costs according to initial treatment modality in stage I cases. Initial stage I treatment 
modalities included ESD, OP, and OP with adjuvant CTx. Total first-year costs for stage I cancer were significantly 
lower for ESD, and, particularly, initial ESD treatment costs were lower than those of the other treatment 
modalities (“<” indicates a significant difference). 
ESD = endoscopic submucosal dissection; OP = surgery; CTx = chemotherapy.
DISCUSSION
Gastric cancer is one of the most common cancers in Korea as 33,000 new patients are 
diagnosed annually [10]. The Department of Health and Human Services in Korea conducts 
cancer screening and recommends that adults ≥40 years old should undergo free mandatory 
upper endoscopy or gastrography every 2 years to detect EGC. This recommendation 
contributes to the recent increase in rates of discovery of EGC in Korea. According to our 
data, screening as an initial diagnostic route is very important for diagnosing EGC. The 
proportion of “due to symptoms” as the initial diagnostic route increased significantly from 
stage I through stage IV cancer.
ESD represents a major treatment for EGC in Korea; according to our data, 42.5% of patients 
with stage I cancer underwent ESD. The treatment modalities used by the National Medical 
Insurance System can affect costs. The Korean Health Insurance Review and Assessment 
Service began to reimburse for ESD of the stomach in November 2011. Thus, our study 
enrolled patients newly diagnosed with gastric cancer since December 2011.
Our data indicate that total first-year costs increased significantly from stage I through stage 
IV cancer. That is, cancer stage was one of the most important factors affecting cancer care 
costs, in agreement with a previous report [11]. Our data show that early detection of gastric 
cancer reduces medical care costs. All total first-year cost categories were lowest in patients 
with stage I disease. However, patient and initial treatment costs were highest in stage III, not 
stage IV, which was probably due to differences in the proportions of treatment modalities 
used. The proportion of combined treatments, such as surgery with chemotherapy, was 
higher in stage III cases than others, whereas costs after initial treatment were much higher 
for patients with stage IV cancer. That is, treatment type and cancer stage were the major 
factors affecting cancer care costs. Thus, early detection of gastric cancer can reduce medical 
care costs, particularly total first-year costs.
Treatment modality was the most important factor affecting medical care costs within 
the same cancer stage. One study in patients with stage III colorectal cancer showed that 
financial burden was highest in patients who used adjuvant chemotherapy [12]. Among stage 
I cases, which accounted for the largest fraction of patients in our study, ESD had the lowest 
total first-year costs compared to those of other treatment modalities. In particular, initial 
treatment costs were much lower for ESD. Therefore, ESD treatment for stage I gastric cancer 
can reduce medical care costs by decreasing initial treatment costs. Our data show that ESD 
for EGC provides a curative local treatment with a low financial burden.
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Table 4. Medical care costs according to initial treatment modalities in stage I
Variables ESD Surgery Surgery with CTx P-value
Total first-year costs ($) 6,028±5,092 11,391±4,778 8,715±7,852 <0.001
Insurer payments 2,113±1,655 5,708±3,455 6,388±4,698 <0.001
Patient payments 1,133±1,246 3,788±2,646 1,363±2,648 <0.001
Cost of initial treatment 1,795±1,292 6,906±3,046 6,534±2,687 <0.001
Cost after initial treatment 2,194±1,992 3,411±3,995 2,254±3,649 <0.001
No. of outpatient visits 8.9±5.2 10.7±7.9 11.8±11.1 <0.001
No. of admissions 1.2±0.8 1.3±1.1 1.6±1.9 >0.050
Data shown are mean±standard deviation.
ESD = endoscopic submucosal dissection; CTx = chemotherapy.
In this study, the proportion of stage I was higher than in other Korean data [13,14]. This is 
probably due to short duration and limited institutions of enrollment. Thus, our results must 
be validated in the future. In addition, we only analyzed direct medical costs because these 
costs are closely associated with cancer characteristics, such as cancer stage and treatment 
options [2]. Some studies have evaluated direct medical costs to investigate trends in initial 
cancer treatment costs [6,15]. A survey, such as the Medical Expenditure Panel Survey, which 
consists of indicators of productivity loss, should be performed to properly investigate 
indirect costs [16-18]. However, our study was retrospective, so a survey was not possible. 
Nonetheless, we infer that, if indirect costs were analyzed, ESD would be associated with 
much lower indirect and direct medical costs than other treatment modalities.
In conclusion, early detection of gastric cancer is important to reduce healthcare costs. 
Especially, ESD can greatly reduce medical care costs of gastric cancer. Thus, screening 
should be done for early detection of gastric cancer.
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